1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus
Correlation Between 1,5-anhydroglucitol and Postprandial Hyperglycemia by Continuous Glucose Monitoring System and Clinical Usefulness of 1,5-anhydroglucitol in Well-controlled Diabetic Patients
1 other identifier
observational
53
1 country
1
Brief Summary
The aim of this study was to evaluate the correlation between 1,5-Anhydroglucitol in patients with HbA1C \<7%, and glycemic excursions as assessed by the continuous glucose monitoring system compared to fructosamine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2010
CompletedFirst Submitted
Initial submission to the registry
July 13, 2010
CompletedFirst Posted
Study publicly available on registry
July 14, 2010
CompletedSeptember 30, 2010
September 1, 2010
July 13, 2010
September 29, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
postprandial hyperglycemia
3days
glucose variability
3 days
Eligibility Criteria
Well-controlled patients with type 2 diabetes with HbA1c\<7%
You may qualify if:
- HbA1C \< 7%
- HbA1c modification \<0.5% in the previous 3 months
- no recent addition of oral hypoglycemic medications or change in insulin dose \>10% previous 3 months
You may not qualify if:
- pregnancy
- anemia (Hb \<10.0 g/dL)
- liver disease (ALT \>2 UNL)
- hypoalbuminemia (albumin \<3.5 g/dL)
- serum creatinine \>2 mg/dL
- acute or chronic renal tubulointerstitial disease
- severe medical illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kyunghee University Medical Center
Seoul, 130-702, South Korea
Biospecimen
serum (HbA1c, fructosamine, 1,5-anhydroglucitol)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jeong-taek Woo, MD, PhD
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
July 13, 2010
First Posted
July 14, 2010
Study Start
February 1, 2008
Study Completion
July 1, 2010
Last Updated
September 30, 2010
Record last verified: 2010-09